不孕女性人群接种新型冠状病毒疫苗后血液指标调查分析  

Investigation and analysis of blood indexes in inferlive female population after vaccination with novel coronavirus vaccine

作　　者：杨斯桀 赵丽娟 李婷[1,2,3,4,5,6,7] 张为民[1,2,3,4,5,6,7] 曹坤 高选[1,2,3,4,5,6,7] YANG Sijie;ZHAO Lijuan;LI Ting;ZHANG Weimin;CAO Kun;GAO Xuan(Department of Medical Laboratory,Reproductive Medicine Research Center,Shandong University/Reproductive Hospital Affiliated to Shandong University,Jinan,Shandong 250012,China;Key Laboratory of Reproductive Endocrinology of Ministry of Education(Shandong University),Jinan,Shandong 250012,China;Shandong Key Laboratory of Reproductive Medicine,Jinan,Shandong 250012,China;Shandong Provincial Clinical Research Center for Reproductive Health,Jinan,Shandong 250012,China;Shandong Technology Innovation Center for Reproductive Health,Jinan,Shandong 250012,China;Key Laboratory of Reproductive Medicine,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan,Shandong 250012,China;Department of Clinical Laboratory,National Research Center for Assisted Reproductive Technology and Reproductive Genetics,Jinan,Shandong 250012,China)

机构地区：[1]山东大学生殖医学研究中心/山东大学附属生殖医院医学检验科,山东济南250012 [2]生殖内分泌教育部重点实验室(山东大学),山东济南250012 [3]山东省生殖医学重点实验室,山东济南250012 [4]山东省生殖健康临床医学研究中心,山东济南250012 [5]山东省生殖健康技术创新中心,山东济南250012 [6]山东第一医科大学附属山东省立医院生殖医学重点实验室,山东济南250012 [7]国家辅助生殖与优生工程技术研究中心医学检验科,山东济南250012

出　　处：《检验医学与临床》2023年第22期3265-3270,共6页Laboratory Medicine and Clinic

基　　金：国家重点研发计划资助项目(2021YFC2700500)。

摘　　要：目的分析新型冠状病毒疫苗接种后不孕女性人群实验室检测指标,对比未接种不孕女性人群相关指标,为新型冠状病毒疫苗接种人群的健康管理随访及疫苗安全性提供参考依据。方法对2021年8-10月于山东大学生殖医学研究中心/山东大学附属生殖医院因不孕症就诊的717例女性患者发放调查问卷,调查新型冠状病毒疫苗接种情况,根据新型冠状病毒疫苗接种情况分为接种组497例,未接种组220例。同时采集患者血液标本进行实验室指标检测,收集和分析调查对象的基本信息和实验室血液检测指标,包括血常规、凝血5项、D-二聚体(D-D)、血清生化指标。结果接种组D-D水平明显高于未接种组,差异有统计学意义(P<0.05);接种组淋巴细胞绝对值、淋巴细胞百分比、血清磷水平明显低于未接种组,差异有统计学意义(P<0.05);两组间其他指标比较,差异无统计学意义(P>0.05)。接种组D-D阳性率(30.4%)高于未接种组(7.7%),差异有统计学意义(P<0.05)。D-D水平与距离第一针及第二针接种时间(天数)均呈负相关(r=-0.142,P=0.002;r=-0.176,P<0.001)。结论新型冠状病毒疫苗接种会引起女性D-D水平升高,淋巴细胞绝对值、淋巴细胞百分比、血清磷水平下降,灭活新型冠状病毒疫苗安全性较好。Objective To analyze the laboratory examination indicators of infertile female population after novel coronavirus vaccine vaccination,and to compare the relevant indicators of infertile female population without vaccination,so as to provide reference for the health management follow-up and vaccine safety of the novel coronavirus vaccine population.Methods From August to October 2021,717 female patients with infertility in Reproductive Medicine Research Center,Shandong University/Reproductive Hospital Affiliated to Shandong University were distributed questionnaires to investigate the vaccination status of the novel coronavirus vaccine.According to the vaccination status of the novel coronavirus vaccine,497 female patients were divided into the vaccinated group and 220 female patients were divided into in non-vaccinated group.At the same time,blood samples of patients were collected for laboratory index detection,basic information and laboratory blood test indicators of the investigation objects were collected and analyzed,including blood routine,5 items of coagulation,D-dimer(D-D)and serum biochemical indicators.Results The levels of D-D in vaccinated group was significantly higher than that in the non-vaccinated group,with statistical significance(P<0.05);the lymphocytes absolute value,lymphocytes percentage and serum phosphorus level in vaccinated group were significantly lower than those in non-vaccinated group,with statistical significance(P<0.05);there was no significant difference on other indicators between the two groups(P>0.05).The positive rate of D-D in vac-cinated group(30.4%)was higher than that in non-vaccinated group(7.7%),the difference was statistically significant(P<0.05).The D-D level correlated negatively with the time(days)from the first and second do-ses(r=-0.142,P=0.002;r=-0.176,P<0.001).Conclusion Novel coronavirus vaccine vaccination can increase the level of D-D,and decrease the lymphocytes absolute value,lymphocytes percentage and serum phosphorus in women.The safety of novel coronaviru

关 键 词：新型冠状病毒疫苗 接种 D-二聚体 

分 类 号：R446.1[医药卫生—诊断学]